Roivant Sciences to join BaseLaunch Accelerator as Healthcare Partner
Roivant becomes the fifth healthcare partner of BaselArea.swiss accelerator program joining Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer and Roche.
BaseLaunch Teams (img: Mathias Mangold)
BaseLaunch provides promising startups with access to non-dilutive funding, industry access, expert knowledge and infrastructure, and integrates them into one of the most dynamic biotech and healthcare ecosystems in Europe. The program is initiated and operated by BaselArea.swiss.
In addition to Roivant, the BaseLaunch healthcare accelerator is backed by Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and other public and private partners. Sascha Bucher, VP and Head of Global Transactions at Roivant and a senior business development and M&A professional with more than 20 years of experience, will join the BaseLaunch Selection Committee.
For Vivek Ramaswamy, Founder and CEO of Roivant, partnering with BaseLaunch underlines the company’s commitment to Basel as a central hub for pharmaceutical innovation in Europe: “Joining the accelerator will allow us to support young and talented entrepreneurs developing promising ideas, and is representative of our desire to become an integral part of the broader life science ecosystem in Basel.”
Alethia de León, Managing Director of BaseLaunch, welcomes Roivant as a Healthcare Partner of BaseLaunch: “We are very excited to have Roivant as a hands-on partner to support and help select promising healthcare startups. Their commitment to our accelerator here in Basel further adds to the strong commitment to this initiative from the leading and highly innovative corporate partners in the healthcare space.”
“Having the world’s leading healthcare companies onboard demonstrates the unique setting of the Basel region as a center for the life sciences,” says Christof Klöpper, CEO of BaselArea.swiss.
In 2017, over 100 projects applied and 11 teams were accepted into BaseLaunch. During the first three months of the program, company founders worked closely with the BaseLaunch team and a network of seasoned professionals to solidify strategy, R&D plans and operations. The companies that were selected for the next phase will be announced shortly.
Applications for 2018 are now open. For more information, visit www.baselaunch.ch
Share this article
You might also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...Read More
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Why CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More
RocketVax raises fresh capital
The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...Read More
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...Read More
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...Read More
Cell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...Read More